Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $40.33 Average Price Target from Analysts

by · The Cerbat Gem

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $40.3333.

A number of brokerages have issued reports on SION. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 8th. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price target for the company. Finally, Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday.

Check Out Our Latest Research Report on SION

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION opened at $42.77 on Friday. The company has a market capitalization of $1.91 billion and a P/E ratio of -8.78. Sionna Therapeutics has a 1-year low of $7.26 and a 1-year high of $45.00. The firm’s 50 day simple moving average is $37.37 and its two-hundred day simple moving average is $26.41.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Ra Capital Management, L.P. sold 25,183 shares of Sionna Therapeutics stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $39.50, for a total value of $994,728.50. Following the sale, the director directly owned 159,033 shares of the company’s stock, valued at approximately $6,281,803.50. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter A. Thompson sold 1,600 shares of the business’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $44.49, for a total value of $71,184.00. Following the completion of the sale, the director owned 3,596,886 shares in the company, valued at $160,025,458.14. This represents a 0.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,604,841 shares of company stock worth $58,312,100. Insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new position in shares of Sionna Therapeutics during the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics during the second quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Sionna Therapeutics during the second quarter valued at $45,000. Virtus Investment Advisers LLC bought a new position in Sionna Therapeutics during the second quarter valued at $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth $117,000.

Sionna Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Read More